Combined treatment with GHRH-R antagonist and EGFR inhibitor significantly extended tumour doubling time from 9.12+/−1.01 days to 14.97+/−1.5 days and provoked a 57.5% decrease in tumour weight as compared to controls (Figure 4B). The gene discussed is EGFR; the disease is neoplasm.